Literature DB >> 29405437

Studying the effect of systemic and biological drugs on intima-media thickness in patients suffering from moderate and severe psoriasis.

A Martinez-Lopez1, G Blasco-Morente1, I Perez-Lopez2, J Tercedor-Sanchez1, S Arias-Santiago1,3.   

Abstract

BACKGROUND: Psoriasis has been related to a large number of cardiovascular risk factors such as hypertension, diabetes mellitus and arteriosclerosis. The increased carotid intima-media thickness (IMT) could be considered to be a marker of generalized arteriosclerosis.
OBJECTIVE: To assess the effect of systemic and biological drugs on psoriatic patients' carotid IMT.
METHODS: A prospective study was performed. We studied 53 patients with moderate and severe psoriasis from our psoriasis dermatological unit, analysing lipid and glucose metabolism and performing a carotid IMT sonography before introduction of systemic and biological drugs. After that, we performed an 8-month closely analytic and sonographic follow-up.
RESULTS: The IMT of the patients with psoriasis treated with biological drugs tended to decrease, although this occurrence was not statistically significant (P = 0.086). The subgroup analysis revealed that patients treated with methotrexate (P = 0.045) and anti-IL-12/23 (P = 0.010) presented a decrease in their IMT levels. This analysis also showed a decrease in glycaemia and insulin levels in patients treated with TNF-alpha inhibitors and ustekinumab.
CONCLUSIONS: Our study suggests that the carotid IMT may benefit from treatment with biological drugs, particularly anti-IL-12/23 and methotrexate in patients suffering from moderate and severe psoriasis. However, larger longitudinal studies should be performed to fully confirm these results.
© 2018 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29405437     DOI: 10.1111/jdv.14841

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  9 in total

Review 1.  Do anti-tumour necrosis factor-α biologics affect subclinical measures of atherosclerosis and arteriosclerosis? A systematic review.

Authors:  Laurence Knowles; Nida Nadeem; Philip J Chowienczyk
Journal:  Br J Clin Pharmacol       Date:  2020-03-08       Impact factor: 4.335

Review 2.  Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences.

Authors:  Wolf-Henning Boehncke
Journal:  Front Immunol       Date:  2018-04-05       Impact factor: 7.561

3.  Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.

Authors:  S Gerdes; A Pinter; C Papavassilis; M Reinhardt
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-10-10       Impact factor: 6.166

4.  Analysis of cardiovascular risk and carotid intima-media thickness in patients with psoriasis.

Authors:  Elaine Cristina Faria Abrahão-Machado; José Alexandre Mendonça; Ana Carolina Belini Bazán Arruda; Luciana Bertoldi Nucci; Marcel Alex Soares Dos Santos
Journal:  An Bras Dermatol       Date:  2020-01-31       Impact factor: 1.896

Review 5.  Management of psoriasis as a systemic disease: what is the evidence?

Authors:  N J Korman
Journal:  Br J Dermatol       Date:  2019-10-15       Impact factor: 9.302

6.  Atherosclerosis attacks in patients with psoriasis vulgaris but without a relationship with the severity and course of the disease.

Authors:  Agnieszka Białecka; Marcin Białecki; Zbigniew Serafin; Rafał Czajkowski
Journal:  Postepy Dermatol Alergol       Date:  2021-09-17       Impact factor: 1.837

Review 7.  Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.

Authors:  J J Wu; A Kavanaugh; M G Lebwohl; R Gniadecki; J F Merola
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-14       Impact factor: 9.228

Review 8.  Oxidative Stress Induced by High Salt Diet-Possible Implications for Development and Clinical Manifestation of Cutaneous Inflammation and Endothelial Dysfunction in Psoriasis vulgaris.

Authors:  Ivana Krajina; Ana Stupin; Marija Šola; Martina Mihalj
Journal:  Antioxidants (Basel)       Date:  2022-06-27

Review 9.  Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say?

Authors:  Marianne de Brito; Zenas Z N Yiu
Journal:  Am J Clin Dermatol       Date:  2021-07-22       Impact factor: 7.403

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.